Register | Login

Contain any new studies withhuman or animal subjects performed by any of the authors.OBINUTUZUMAB, A NOVEL HUMANIZED TYPE II MABObinutuzumab (GA101) is a novel, type II, glycoengineered, humanized anti-CD20 mAb that has been developed to address the need for novel therapeutics with higher activity than rituximab. The glycoengineering process post-translational used in thedevelopment of this agent

Who Voted for this Story


Instant Approval Social Bookmarking Websites

3d gallery live wallpaper

Pligg is an open source content management system that lets you easily create your own social network.